Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole
Xueru Wang,
No information about this author
Zijie Li,
No information about this author
Shihui Kuai
No information about this author
et al.
CNS Neuroscience & Therapeutics,
Journal Year:
2024,
Volume and Issue:
30(5)
Published: May 1, 2024
Abstract
Aims
The
hippocampus
has
been
reported
to
be
morphologically
and
neurochemically
altered
in
schizophrenia
(SZ).
Hyperlocomotion
is
a
characteristic
SZ‐associated
behavioral
phenotype,
which
associated
with
dysregulated
dopamine
system
function
induced
by
hippocampal
hyperactivity.
However,
the
neural
mechanism
of
underlying
hyperlocomotion
remains
largely
unclear.
Methods
Mouse
pups
were
injected
N
‐methyl‐
D
‐aspartate
receptor
antagonist
(MK‐801)
or
vehicle
twice
daily
on
postnatal
days
(PND)
7–11.
In
adulthood
phase,
one
cohort
mice
underwent
electrode
implantation
field
CA1
for
recording
local
potentials
spike
activity.
A
separate
surgery
allow
calcium
imaging
while
monitoring
locomotion.
Lastly,
effects
atypical
antipsychotic
(aripiprazole,
ARI)
evaluated
Results
We
found
that
theta
oscillations
enhanced
MK‐801‐treated
mice,
but
correlation
coefficient
between
spiking
activity
oscillation
was
reduced.
Consistently,
although
rate
amplitude
transients
neurons
increased,
their
synchrony
locomotion
speed
disrupted.
ARI
ameliorated
perturbations
produced
MK‐801
treatment.
Conclusions
These
results
suggest
disruption
coordination
may
underly
neuropathological
SZ.
Language: Английский
Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials
Junyu Chen,
No information about this author
Yu‐Pei Yuan,
No information about this author
Ying Hu
No information about this author
et al.
Neuropsychiatric Disease and Treatment,
Journal Year:
2024,
Volume and Issue:
Volume 20, P. 1667 - 1675
Published: Sept. 1, 2024
The
adjunctive
therapeutic
potential
of
simvastatin
in
schizophrenia
treatment
has
generated
interest
due
to
its
anti-inflammatory
and
neuroprotective
properties.
This
meta-analysis
aims
assess
the
efficacy
as
an
adjunct
for
schizophrenia,
synthesizing
results
from
various
controlled
trials.
Language: Английский